World News
-
Bristol Myers Squibb bets US$15.2B on Hengrui partnership to accelerate global drug pipeline
Hengrui will oversee the initial human clinical studies for the immunology assets licensed from BMS, a move intended to speed up proof-of-concept data generation.
-
Novartis breaks ground on Texas’ first radioligand therapy site to secure U.S. cancer supply chain
The Denton facility will become Novartis’ first manufacturing site in Texas and its fifth radioligand therapy production site in the country.
-
Bright Uro expands Glean platform with FDA-cleared abdominal sensor for catheter-free urodynamics
Urodynamics assesses how the bladder, urethra, and sphincters store and release urine to identify causes of leakage or obstruction.
-
Roche to buy PathAI for up to US$1.05B to advance AI-driven digital pathology
The acquisition builds on an established collaboration between Roche and PathAI that began in 2021 and expanded in 2024 to include the development of AI-enabled companion diagnostic algorithms.
-
GSK bets US$1B on SiranBio’s ALK7 siRNA to disrupt the obesity market
The agreement excludes China, Hong Kong, Macau, and Taiwan, where SiranBio will retain rights.
-
Angelini Pharma to acquire Catalyst Pharmaceuticals in US$4.1B U.S. rare disease expansion
Catalyst Pharmaceuticals, listed on Nasdaq in 2006, has evolved into a focused rare disease company with strong commercial momentum.
-
Madrigal expands MASH pipeline with US$1B licensing deal for Arrowhead’s siRNA therapy
Under the agreement, Madrigal will take over the development, manufacturing, and commercialisation of Arrowhead’s investigational therapy, ARO-PNPLA3.
-
Olympus partners with EndoRobotics to expand robot-assisted gastrointestinal procedures
The robot-assisted technologies under this agreement respond directly to this challenge by improving clinical outcomes and reducing procedural complications.
-
Bayer to acquire Perfuse Therapeutics in US$2.45B deal to strengthen its ophthalmology pipeline
The acquisition comes as Bayer seeks to reinforce its position in ophthalmology amid growing biosimilar competition facing Eylea, which it co-developed with Regeneron.
-
Eli Lilly invests US$4.5B more in Indiana manufacturing to increase production capacity
The additional funding will enhance two key facilities within the Lebanon complex, known collectively as the LEAP Research and Innovation District.